ORIGINAL ARTICLE

Novel opioid-neurotensin-based hybrid peptide with spinal long-lasting antinociceptive activity and a propensity to delay tolerance development

Karolina Frączek\textsuperscript{a}, Mattia Ferraiolo\textsuperscript{b}, Emmanuel Hermans\textsuperscript{b}, Magdalena Bujalska-Zadrożyń\textsuperscript{a}, Kaja Kasrello\textsuperscript{c}, Anna Erdei\textsuperscript{d,e}, Kamila Kulik\textsuperscript{a}, Agnieszka Kowalczyk\textsuperscript{a}, Piotr Wojciechowski\textsuperscript{f}, Dorota Sulejczak\textsuperscript{g}, Piotr Sosnowski\textsuperscript{h}, Sebastian Granica\textsuperscript{i}, Sandor Benyhe\textsuperscript{j}, Katarzyna Kaczynska\textsuperscript{f}, Łukasz Nagrała\textsuperscript{j}, Artur Stolarczyk\textsuperscript{j}, Agnieszka Cudnoch-Jedrzejewska\textsuperscript{c}, Patrycja Kleczkowska\textsuperscript{a,*}

\textsuperscript{a}Department of Pharmacodynamics, Centre for Preclinical Research (CBP), Medical University of Warsaw, Warsaw 02-097, Poland
\textsuperscript{b}Laboratory of Neuropharmacology, Institute of Neurosciences, Université Catholique de Louvain, Brussels B-1200, Belgium
\textsuperscript{c}Department of Experimental and Clinical Physiology, Centre for Preclinical Research (CBP), Medical University of Warsaw, Warsaw 02-097, Poland
\textsuperscript{d}Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, Szeged H-6701, Hungary
\textsuperscript{e}Doctoral School of Therapeutical Medicine, University of Szeged, Szeged H-6720, Hungary
\textsuperscript{f}Department of Respiratory Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw 02-106, Poland
\textsuperscript{g}Department of Experimental Pharmacology, Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw 02-106, Poland
\textsuperscript{h}Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw 02-106, Poland
\textsuperscript{i}Department of Neuropeptides, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw 02-106, Poland
\textsuperscript{j}Department of Pharmacognosy and Molecular Basis of Phytotherapy, Faculty of Pharmacy, Medical University of Warsaw, Warsaw 02-097, Poland
\textsuperscript{k}Department of Orthopaedics and Rehabilitation, Medical University of Warsaw, Warsaw 04-749, Poland

Received 1 November 2019; received in revised form 1 March 2020; accepted 20 April 2020

*Corresponding author. Tel.: +48 22 1166127.
E-mail address: hazufiel@wp.pl (Patrycja Kleczkowska).

Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2020.04.014
2211-3835 © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Novel opioid-neurotensin-based hybrid peptide with spinal long-lasting antinociceptive activity

1. Introduction

Opioid-based hybrid structures have been proposed as a putative valuable alternative to the use of strong opioids administered alone or in combination with other drugs. The development of such novel compounds for pain management is directed by the objective of reducing possible adverse side effects as well as to minimize the risk for drug interactions. Indeed, prolonged use of opioids that are considered the most potent and effective analgesics to date is commonly accompanied by burdensome side effects (e.g., constipation, vomiting, nausea, tolerance, physical dependence, itch, motor impairment, and an increased risk of respiratory depression). Therefore, much effort is dedicated to the discovery of innovative drugs that would retain their opioid activity, but were less likely to cause severe adverse effects that require medical intervention.

In our recent work, we presented several hybrid compounds that encompassed two pharmacologically distinct pharmacophores confined in one molecular scaffold, which resulted in potent drug-like molecules with dual activity. These two chimeras (i.e., AA3052 and [Ile]^2[PK20]) were identified as promising pain killers, devoid of several opioid-induced side effects. This illustrates how administration of two active entities joined chemically into one molecule may significantly improve physicochemical and pharmacokinetic properties of individual molecules. This enables the drug to reach its specific target without modifying other properly functioning processes in the body. Additionally, apart from an improved biological activity, such drugs could also prove useful for the treatment of other comorbidities.

In the present study, we focused on a novel hybrid that combines opioid and neurotensin (NT)-like fragments. Of note, neurotensin was previously documented for its opioid-independent role in pain modulation. Also, by inhibiting dopamine release, NT may prove efficient in modulating the rewarding effect of opioids. Herein presented is an opioid-derived hybrid peptide codenamed PK23, the third compound of the series designed by our group that encompasses an NT pharmacophore. This structure, however, differs from both PK20 or [Ile]^2[PK20] by i) the ω-amino acid residue located in the second position from the N-terminal, as well as ii) the presence of unnatural amino acids in the first and ninth positions. This bivalent drug lacks both the dimethyl tyrosine and tert-leucine present in PK20 that could result either in a lower μ-opioid receptor binding affinity or reduced plasma stability. Additionally, incorporation of polar amino acid residues in the chain, particularly alanine, may result in lower blood—brain barrier (BBB) permeability. We herein investigated how these modifications impact on the biological activity of this new hybrid compound. Apart from preliminary in vitro studies, we evaluated the antinociceptive properties of PK23 upon various delivery routes and examined some possible undesirable side effects arising from its repeated administration.

2. Materials and methods

2.1. Drugs and chemicals

The opioid—NT hybrid peptide—PK23 (Ytr-ω-Ala-Phe-Phe-Lys-Lys-Pro-Phe-Ile-Leu-OH) was designed and prepared at the Department of Neuropeptides of the Mossakowski Medical Research Centre PAS (Warsaw, Poland) by manual solid-phase peptide synthesis using N-fluorenylmethoxycarbonyl (Fmoc) chemistry. Morphine was obtained from Polfa (Warsaw, Poland) and similarly to the chimera tested, was dissolved in saline. NT as well as naltrexone, an opioid receptor antagonist together with SR 48692 and NTRC 824, NTS1 and NTS2 receptor selective antagonists, respectively, were purchased from Tocris Bioscience (Germany). The anaesthetic drugs ketamine and xylazine were purchased from Biowet (Pulawy, Poland) while isoflurane was obtained from Baxter (Cracow, Poland).

Guanosine-5′-[γ-35S]triphosphate (1000 Ci/mmol, [35S]GTPγS) was purchased from Hartmann Analytic (Braunschweig, Germany), whereas [3H]DAMGO was purchased from PerkinElmer (Waltham, MA, USA). EDTA, bovine serum albumin (BSA), bestatin, bacitracin and phosphoramidon were purchased from Sigma—Aldrich (St. Louis, MO, USA).

2.2. Animals

Adult male Wistar rats (225–250 g body weight) were provided by the Animal facility of the Medical University of Warsaw. The animals were housed under standard laboratory conditions (at ambient temperature of 22 ± 2°C, 12–12 h light–dark cycle).
Soon after weaning, animals were housed separately in plastic cages with soft bedding, food and water available at all times, except during the course of the experiments.

The experimental protocols for animal usage were approved by the II Local Commission for the Care and Use of Laboratory Animals for Experimental Procedures in Warsaw (Permit numbers: 27/2015 and 167/2016) and adhered to guidelines published in the European directive 2010/63/EU on the protection of animals used for scientific purposes.

2.3. Ligand-stimulated functional [35S]GTPγS assay

2.3.1. Cell culture and membrane preparation

2.3.1.1. Opioid receptors. Forebrain membrane fractions were prepared according to the method previously described by Benyhe et al. Briefly, rats were decapitated and the whole brain (without cerebellum) was quickly removed and homogenized in 30 volumes (mL/g wet mass) of 50 mM Tris-EGTA buffer and centrifuged at 18,000 g. The resultant pellets were resuspended in 50 volumes of 50 mM Tris-EGTA buffer (30 g/mL) and then incubated for 30 min at 37 °C. Subsequently, the centrifugation step was repeated. The final pellets were resuspended in 5 volumes of 50 mM Tris-EGTA buffer (7.4) containing 0.32 mM sucrose and stored at −80 °C until future use. For binding assays, membranes were thawed and then resuspended in 50 mM Tris-EGTA (pH 7.4) and centrifuged at 18,000 g for 20 min at 4 °C in order to remove sucrose. The resulting pellets were suspended in ice-cold TEM buffer (50 mM Tris-EGTA, 2 mM EDTA, 1 mM EGTA, 5 mM MgCl2) to obtain a protein concentration of approx. 40 µg/mL per assay.

2.3.1.2. NTS1 receptors. Transfected CHO cells expressing the rat NTS1 were grown in MEM alpha medium supplemented with 10% foetal calf serum, 85 µg/mL streptomycin and 85 U/mL penicillin. Cultures were maintained at 37 °C in a humidified atmosphere of 5% CO2—95% air.

2.3.2. GTPγS binding assays for µ-opioid receptors

Membrane fractions from rat brain and spinal cord (~10 µg of protein/tube) were incubated at 30 °C for 60 min in Tris-EGTA buffer (50 mM Tris-Cl, 1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, pH 7.4) containing [35S]GTPγS (0.05 mM/mL) and increasing concentrations (10^-9 to 10^-5 M/mL) of the compounds tested in the presence of 30 mM GDP. Incubation was terminated by addition of 0.1 M Gpp(NH)p. The reaction was initiated by addition of [35S]GTPγS and terminated by filtration of the samples through Whatman GF/B glass fibre filters. Filters were washed three times with ice-cold 50 mM Tris-Cl buffer (pH 7.4) using the Brandel M24R Cell Harvester, then dried. Bound radioactivity was detected in a UltimaGold™ scintillation cocktail (Packard, Meriden, CT, USA). Agonist-induced receptor-mediated G protein stimulation was expressed as percentage over the specific [35S]GTPγS binding observed in the absence of ligands (basal activity). [35S]GTPγS binding assays were performed in duplicate and all experiments were carried out three times independently.

2.3.3. [35S]GTPγS binding assays for CHO cells stably expressing the NTS1 receptors

The specific binding of [35S]GTPγS was measured in cell homogenates as previously described. Briefly, cell homogenates (25–50 µg) were resuspended in binding buffer (50 mM Tris-Cl (pH 7.4) containing 5 mM MgCl2, 1 mM GDP, 150 mM NaCl and 1 mM dithiothreitol). The homogenate was incubated for 40 min in the presence of 0.05 mM [35S]GTPγS at 37 °C. Non-specific binding of [35S]GTPγS was measured in the presence of 0.1 mM Gpp(NH)p. Incubation was terminated by addition of 3 mL ice-cold binding buffer and the suspension was immediately filtered through GF/B glass fibre filters and washed twice with the same buffer using a 24-channel Brandel Harvester (SEMAT, St Albans, Hertfordshire, UK). Radioactivity trapped on the filter was estimated by scintillation counting. Results are expressed as mentioned above (see Section 2.3.2).

2.4. Surgical procedures performed for further determination of drug-mediated analgesia

2.4.1. Intracerebroventricular catherization

For the intracerebroventricular (central, i.c.v.) drug administration, rats were implanted with canulas according to the previously published protocol. Briefly, rats were deeply anesthetized with a mixture of ketamine (87 mg/kg, i.p.) and xylazine (13 mg/kg, i.p.). A longitudinal skin incision was made along the midline to expose the skull. Polyethylene canulas (PE 10, Intramedic™ Polyethylene Tubing, Clay–Adams Company, New York, USA; ID = 0.28 mm, OD = 0.61 mm, and 13 cm in length) were inserted into the right lateral ventricle. The canula was secured by dental cement (Ketac™ Cem radiopaque, 3M ESPE, Germany). After surgery, animals were placed in separate cages and the experiment began on the fifth day after surgery. Animals showing signs of motor impairment were excluded from the experiment and immediately euthanized.

2.4.2. Intrathecal catherization

Intrathecal (spinal, i.t.) administration of test drugs was performed using a method previously described by Yaksh and Rudy. Rats were anaesthetized with a mixture of ketamine/xylazine as detailed here above and placed in a stereotaxic head holder. A silicone catheter (PE 10, Intramedic™ Polyethylene Tubing, Clay–Adams Company, New York, USA; ID = 0.28 mm, OD = 0.61 mm, and 13 cm in length) was inserted into the intrathecal space through the atlanto-occipital membrane, positioning the tip at the L1 spinal level. Dental cement was used to fix the guide cannula to the skull. After surgery, animals with no obvious motor deficits were allowed to recover for 4 days before pharmacological experiments. However, during this time, rats were habituated to the experimenter in order to minimize stress. Animals showing paralysis or other signs of motor impairment after recovering from anaesthesia were immediately euthanized.

After each canulaulation (i.c.v. or i.t.) the cannula/catheter placement was verified by an injection of 5% methylene blue and further checking for distribution within either the cerebroventricular or spinal subarachnoid space, respectively.
2.5. Surgical procedures performed for further determination of drug-induced hypotension and respiratory depression

Rats were i.t. catheterized as described in Section 2.4.2. For measurements of cardiovascular and respiratory parameters, animals were anesthetized with an intraperitoneal injection of 600 mg/kg urethane and 120 mg/kg alpha-chloralose (Sigma—Aldrich, Poznan, Poland). The depth of anaesthesia was assessed by monitoring any changes in blood pressure to a noxious pinch to the tail. Next, animals were placed in a supine position on a heating pad so that rectal temperature was kept between 37 and 38 °C. Tracheotomy was performed in the neck. A catheter was inserted into the femoral artery. Cardiovascular and respiratory responses to i.t. PK23 (10 nmol/rat) injection were examined right after the end of surgical procedures.

2.6. Drug administration and treatment

2.6.1. Acute pain model

The PK23 hybrid peptide was dissolved in sterile 0.9% NaCl and brought to room temperature. For single i.t. and i.c.v. injections, four various dosages of the peptide (0.5, 2, 5 and 10 nmol/rat) were administered through the catheter at a maximal volume of 10 and 3 µL, respectively. Noteworthy, the dose range used in the current experiment, in particular for i.t. administration, is similar to those used in our previous studies8,12, so the impact of amino acids replacement on drug biological activity could be observed. For i.p. administration, two doses of 1.8 and 2.7 µmol/rat were used. Control animals received saline. In order to determine the involvement of the opioidergic and NTergic systems in analgesia, used. Control animals received saline. In order to determine the involvement of the opioidergic and NTergic systems in analgesia, used. Control animals received saline. In order to determine the involvement of the opioidergic and NTergic systems in analgesia, used. Control animals received saline. In order to determine the involvement of the opioidergic and NTergic systems in analgesia, used. Control animals received saline. In order to determine the involvement of the opioidergic and NTergic systems in analgesia, used. Control animals received saline. In order to determine the involvement of the opioidergic and NTergic systems in analgesia, used. Control animals received saline. In order to determine the involvement of the opioidergic and NTergic systems in analgesia, used. Control animals received saline. In order to determine the involvement of the opioidergic and NTergic systems in analgesia, used. Control animals received saline.
2.8. Determination of drug-induced cardiovascular and respiratory effects in anesthetized rats

Blood pressure and heart rate in rats challenged with i.t. PK23 (10 nmol/rat) were measured via a catheter inserted into the femoral artery and connected to a BP-2 blood pressure monitor (Columbus Instruments, Columbus, OH, USA). Tidal volume signals were recorded with a pneumotachograph head attached to the tracheal cannula connected with a Research Pneumotach System (RSS 100 HR, Hans Rudolph Inc., Kansas City, MO, USA) and a computerized recording system (KORR Medical Technologies Inc., Salt Lake City, UT, USA) for measuring respiratory frequency (f), tidal volume (V\textsubscript{T}), and minute ventilation (V\textsubscript{E}). The recordings were registered on an Omnilight 8M36 apparatus (Honeywell, Tokyo, Japan).

The values of f, V\textsubscript{T}, V\textsubscript{E}, mean arterial blood pressure (MAP) and heart rate (HR) were calculated by averaging the variables measured for five sequential respiratory cycles just before drug injection, and at chosen time points of post–challenge phase. The maximum values were chosen from the computed time points ranging from 1 to 5 min.

2.9. In vitro plasma stability study

For plasma stability studies of PK23, control rats (n = 3) were anesthetized with isoflurane and whole blood samples were collected via cardiac puncture into violet BD Vacutainer tubes. Blood was centrifuged for 4 °C for 10 min at 18,000 rpm (Microfuge 20, Beckman Coulter Life Science, Poland) to remove the fibrin clot and plasma was carefully transferred into eppendorf tube using a pipette. Fifty μL of PK23 solution in water (1000 μg/mL) was added to 400 μL of plasma sample and incubated at 37 °C for up to 24 h (incubation times were set to 0, 1, 2, 4, 6, 8, 12 and 24 h). Prior to UHPLC analysis, PK23-enriched plasma samples (25 μL) were quenched with 200 μL of acetonitrile for protein precipitation, vortex mixed for 1 min, kept at 4 °C for 15 min and then centrifuged at 4 °C for 15 min at 17,000 rpm. The resulting supernatants (ca. 100 μL) were transferred into vials with glass inserts and analyzed by UHPLC–DAD–MS. UHPLC—DAD–MS analysis was conducted using a Dionex Ultimate 3000RS system coupled with an Amazon SL ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany). The ion trap AmazonSL mass spectrometer was equipped with an ESI interface. The eluate was introduced into the ESI interface of the mass spectrometer without splitting. The parameters for the ESI source were as follows: nebulizer pressure 40 psi; dry gas flow 9 L/min; dry temperature 145 °C; and capillary voltage 4.5 kV. The analysis was carried out using scanning from m/z 70 to 2200. Mass spectra were recorded in negative-ion mode. The separation was carried out on a Kinetex XB-C18 (150 mm × 2.1 mm × 1.7 μm, Phenomenex, Torrance, CA, USA) column maintained at 25 °C. The mobile phases were 0.1% HCOOH in water (A) and 0.1% HCOOH in acetonitrile (B), and elution was conducted with the following gradient: 0 min, 5% B; 15 min, 50% B; and 20 min, 65% B. The flow rate was 0.3 mL/min, and the sample injection volume was 5 μL. The UV—Vis spectra of the detected compounds were recorded over the 190—450 nm range. The chromatogram was recorded at 205 nm. Quantification of PK23 was performed using a MS detector. Extracted ion chromatograms (EIC) for all samples at m/z = 1272 amu were calculated and the area of the detected peak at ca.12.6 min was measured.

Calibration curves based on the amount injected (ng) versus peak area were plotted. Linear regression fit was used for the data obtained. Residual compound concentration in plasma was calculated. Next, the plot showing the logarithm of the remaining fraction of PK23 vs. incubation time was generated. The linear fit model was used. The t\textsubscript{1/2} was calculated using the slope (b) of the generate curve according to the following formula: t\textsubscript{1/2} = 0.693/b.

2.10. Statistical analyses

Group size was determined based on power analysis. Additionally, block randomization method was used in order to allocate animals into respective treatment groups. The experimenters were all blinded to treatments. Data were analysed with the use of GraphPad Prism v.5.0 software (GraphPad Software, San Diego, CA, USA, www.graphpad.com). Figures were generated by the same software, except for data obtained from binding studies. In this case, experimental data were analysed and graphically processed by the GraphPad Prism software (version 4.00 for Windows, GraphPad Software). In binding experiments, displacement curves were fitted by non-linear regression using the one-site competition fitting option with no ligand depletion model. Results were expressed as EC\textsubscript{50} values ± SEM (standard error of mean).

Results from behavioral studies were expressed as a percent of the maximal possible effect (MPE, %) using Eq. (1):

\[
\text{MPE} \% = \frac{(pdr - br)}{(co - br)} \times 100
\]

where pdr, br and co refer to post drug response, baseline response and cut-off value, respectively. Raw data from nociceptive tests were converted to AUC, calculated by the trapezoidal rule, at specific time points. Statistical analysis of the in vivo time–course curves was conducted by two-way or one-way ANOVA followed by the Bonferroni’s post-test, unless otherwise stated. Whereas corresponding AUC data were analyzed using one-way ANOVA followed by the Dunnett’s post hoc test. Differences in values were considered significant at *P < 0.05, **P < 0.01 and ***P < 0.001.

| Peptide    | Potency pEC\textsubscript{50}±SEM (EC\textsubscript{50}, nmol/L) | Efficacy (F\textsubscript{max}), stimulation±SEM (%) over the basal |
|------------|---------------------------------------------------------------|---------------------------------------------------------------|
|            | Opioid receptor mediated effect | NTS1 receptor mediated effect | Opioid receptor mediated effect | NTS1 receptor mediated effect |
| Brain      | Spinal cord | Brain | Spinal cord | Brain | Spinal cord |
| Morphine   | 8.46 ± 0.10 (3.5) \textsuperscript{25} | 6.92 ± 0.16 (120) | N/A          | 146.9 ± 4.7 \textsuperscript{25} | 98.6 ± 5.0 |
| NT         | N/A         | N/A         | 8.50 ± 0.20 (3.31) \textsuperscript{8} | N/A          | N/A |
| PK23       | 6.71 ± 0.51 (197) | 5.91 ± 0.25 (1222) | 6.95 ± 0.16 (113) | 110.5 ± 2.5 | 53.7 ± 7.2 |

The values of f, V\textsubscript{T}, V\textsubscript{E}, mean arterial blood pressure (MAP) and heart rate (HR) were calculated by averaging the variables measured for five sequential respiratory cycles just before drug injection, and at chosen time points of post–challenge phase. The maximum values were chosen from the computed time points ranging from 1 to 5 min.
Figure 1  Time- and dose-dependent analgesic effect induced by (A) i.c.v., (B) i.t., and (C) i.p., and (D) i.v. PK23 administration. The analgesic effect of a single bolus administration of PK23 in rats was measured with the tail-flick test. Dose–response curves derived from AUC calculated after PK23 treatment are presented as insert within each panel. Individual data were compared to the control group injected with saline. Results were analysed either with two-way ANOVA followed by Bonferroni’s post-test (dose–response curves) or one-way ANOVA followed by Dunnett’s post hoc test (AUC calculation). Significant differences between animals receiving PK23 and control groups were indicated as: *P < 0.05, **P < 0.01 and ***P < 0.001, respectively. n = 6–7 rats/group. $F_{4,120} = 44.89 (P < 0.0001)$ and $F_{4,30} = 10.26 (P < 0.0001)$ for i.c.v. administration; $F_{4,120} = 279.23 (P < 0.0001)$ and $F_{4,30} = 118.70 (P < 0.0001)$ for i.t. administration; $F_{4,72} = 4.70 (P = 0.0020)$ and $F_{2,18} = 6.34 (P = 0.0082)$ for i.p. injection, and $F_{4,80} = 151.02 (P < 0.0001)$ and $F_{3,20} = 76.01 (P < 0.0001)$ for i.v. administration.
The ED_{50} was defined as the drug dose that induced a 50% MPE measured by the tail-flick test. ED_{50} values were calculated using either the linear regression method (i.v. drug administration) or nonlinear sigmoidal dose response (i.t. drug administration).

Differences in ED_{50} values for tolerance study were considered significant when confidence intervals did not overlap.

Cardiovascular and respiratory parameters were expressed as means ± SEM. Non-parametric U Mann–Whitney test was used for the comparisons of parameters between PK23 and saline treatments, while the Wilcoxon’s signed-ranks test was used for comparisons within groups. A \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. PK23 stimulation of opioid and NTS1 receptors

The effect of PK23 on the G protein activation efficacy (\( E_{\text{max}} \)) and potency (\( pE_{\text{EC}_{50}} \)) was tested in [\( ^{35} \text{S} \)]GTP\( \gamma \)S binding assays in comparison with morphine and NT (Table 1). Analyses of concentration–response curves from data obtained both in spinal cord or brain samples permitted to derive \( pE_{\text{EC}_{50}} \) values supportive for an interaction of PK23 with both types of receptors tested. Importantly, similarly to morphine, the potency and efficacy of this chimeric peptide at \( \mu \)-opioid receptors appeared greater in brain than spinal cord homogenates.

3.2. Dose- and time-dependent antinociceptive response induced by PK23

In the radiant heat tail-flick test, PK23 exhibited a time- and dose-dependent analgesic effect after supraspinal (i.c.v.), spinal (i.t.) and peripheral (i.v.) administration (Fig. 1). Since ED_{50} represents a dose required to achieve 50% of the maximal effect, there was no possibility to produce the ED_{50} value for i.c.v PK23. This resulted from the fact that higher doses generated serious adverse effect that did not allow further testing, while lower shown less that 50% activity; although for PK23 (i.t.) the ED_{50} value was 4.38 nmol/rat (i.t.). The maximal efficacy of PK23 was obtained after i.t. administration (Fig. 1B). A strong pain-relieving effect, with the MPE (%) value of 93.20 ± 2.65%, was obtained 30 min-post-injection with the highest PK23 dose tested (10 nmol/rat). The response to PK23 was transient as the post-treatment MPE (%) values reached baseline at 90 min after administration. On the contrary, the weakest activity was observed in rats receiving an i.p. administration of PK23 (Fig. 1C). Unexpectedly, whilst the lower dose of 10 mg/kg resulted in a modest analgesic effect [MPE (%) = 9.45 ± 0.81%] seen in the first 30 min post-administration, a trend for increased pain sensitivity was observed when injected at a dose of 15 mg/kg. The responses at both doses were calculated to be statistically significant at 15 min (\( P < 0.01 \)), 30 min (\( P < 0.001 \)) and 60 min (\( P < 0.001 \)), respectively [data not shown in Fig. 1; \( F_{4,48} = 9.21 \) (\( P < 0.0001 \)) and \( F_{1,12} = 50.50 \) (\( P < 0.0001 \)).

PK23 also induced a modest antinociceptive effect in the tail-flick test following i.c.v. administration (Fig. 1A). In fact, maximal analgesia was obtained with a dose of 10 nmol/rat and reached MPE (%) values of 15.79 ± 1.41% (30 min post-administration). However, central administration of PK23 at this dose resulted in visible abnormalities of motor behavior manifested by short barrel rotation.

Intrathecal administration of 10 nmol/rat of PK23 produced a comparable analgesic effect as an equimolar dose of morphine (Fig. 2). However, these similarities in terms of response magnitude were observed only at 15 min [MPE (%) = 84.50 ± 3.84% for morphine and MPE (%) = 80.71 ± 4.11% for PK23] and 30 min post-administration [MPE (%) = 86.23 ± 4.76% for morphine and MPE (%) = 93.20 ± 2.65% for PK23]. A noticeable and significant attenuation of PK23-induced effect in comparison to morphine was noticed at later time points (\( P < 0.001 \)).

Intravenous (i.v.) PK23 administration revealed that this compound could also induce a dose-dependent antinociceptive response (ED_{50} = 2.33 mg/kg) as measured by the tail-flick assay. The maximal possible effect was observed for the 5 mg/kg dose (Fig. 1D) at the 5 min time point with an MPE (%) value equal to 73.55 ± 4.69%. After this time, the pain-relieving effect (practically for every dose tested) decreased dramatically.

3.3. Contribution of opioid and NTS receptors to PK23-mediated spinal analgesia

Animals were pre-injected with specific competitive antagonists of opioid receptors (NTX), the NTS1 (SR48692) or NTS2 receptors (NTRC 824) in order to delineate the involvement of these molecular targets in the effect of PK23. Pharmacological blockade of the \( \mu \)-opioid and NTS1 receptors was found to significantly attenuate the analgesic effect obtained with i.t. PK23 (Fig. 3). Thus, injection of NTX (26.4 nmol/rat) considerably reduced the analgesic response evoked by PK23 throughout the 120 min observation period with maximal inhibition after 15 min [from MPE (%) = 80.71 ± 4.11% for PK23 alone to MPE (%) = 12.12 ± 1.89% observed after co-administration with NTX] and 30 min [from MPE (%) = 93.20 ± 2.65% for PK23 alone to MPE (%) = 21.95 ± 2.94% observed after co-administration with NTX]. Similarly, administration of SR 48692 resulted in an inhibition of the PK23 pain-relieving effect at both 15 min [up to MPE (%) = 53.36 ± 2.99%] and 30 min [up to MPE (%) = 55.90 ± 5.71%] post-injection, respectively. In fact,
two-way ANOVA revealed significant differences ($P < 0.001$) between time-course curves and AUC values for PK23 alone or PK23 with NTX and SR 48692, respectively (Fig. 3A and B). In contrast, NTRC 824 (17.5 nmol/rat) did not influence the analgesic response to PK23 ($P > 0.05$). Estimation of the AUC for NTRC 824 with PK23 indeed confirmed the absence of inhibition, suggesting the lack of involvement of NTS2 receptor.

3.4. Assessment of the occurrence of tolerance following administration of PK23

3.4.1. Tolerance development

Repeated i.t. administration of the chimeric compound PK23 for 8 consecutive days was performed in order to determine whether PK23-induced effects would decline over time as a consequence of tolerance. Although tolerance developed, likely resulting from the activity of the opioid pharmacophore moiety, the loss of PK23-induced analgesia was induced at a slower rate than for morphine administered at the same dose of 10 nmol/rat (Fig. 4B). In fact, on day 8 while the MPE (%) value calculated for PK23 was estimated at 35.73 ± 5.16%, the MPE (%) for morphine was -16.89 ± 1.52%, reflecting the development of hyperalgesia (Fig. 4B). Additionally, intrathecal PK23 chimera or morphine was reported to exert different pharmacological actions mediated by variations in receptor interactions.

Differences in tolerance development between tested drugs were supported by the shifts in ED50 (with 95% CI), based upon peak dose–response relationship values, and was shown in Table 2. Indeed, a repeated morphine treatment produced a 3.2-fold increase in the acute ED50 values in the tail-flick test reflecting
a significant loss of analgesic potency. In the contrary, chronic treatment of a tested hybrid resulted only in 1.22-fold increase of the morphine ED₅₀ values. Thus, development of tolerance to intrathecal PK23 seems to be delayed as compared with morphine.

In the study of cross-tolerance, animals treated for 8 consecutive days with PK23 were found to retain analgesic response to single injection of morphine (i.t.) on day 9 compared with the saline-treated group. In these conditions, the magnitude of the response to morphine [MPE (%) = 33.10 ± 5.44%] was decreased compared to day 1 and was similar to the response to PK23 alone measured on day 8 [MPE (%) = 35.73 ± 5.16%] (Fig. 5A). Similarly, in an analogous study (Fig. 5B), administration of PK23 on day 9 neither stopped nor reduced/improved hyperalgesia induced by morphine (day 8, i.t.).

### Table 2. ED₅₀ values for morphine and PK23 analgesia in the rat tail-flick test after repeated intrathecal treatment.

| Group   | ED₅₀ value (nmol, i.t.)a | Day 3 | Day 4 | Shift |
|---------|--------------------------|-------|-------|-------|
| PK23    | 4.38 (3.86–4.96)         | 5.36  | 6.47–6.17 | 1.22* |
| Morphine| 2.82 (2.33–3.41)         | 9.03  | 7.03–11.61 | 3.20  |

The ED₅₀ values were calculated from dose–response curve. For morphine-treated group, dose–response curve should have been generated following 3 days treatment period due to the serious side effects (e.g., hyperalgesia) revealing in further days of administration and resulting in lack of dose-dependent effect. *Statistically insignificant.  

### 3.4.3. PK23 induces less scratching and grooming behaviour

The PK23 hybrid peptide was found to elicit time-dependent scratching and grooming behaviours in rats (Fig. 7A–D). However, at a dose of 10 nmol/rat i.t., the number of grooming events induced by the chimeric compound was significantly lower as compared to morphine-treated rats either on day 1 (F₂,₁₅ = 13.54, P = 0.0004) or day 9 (F₂,₁₅ = 26.79, P < 0.0001; Fig. 7A and C, respectively). Similarly, on day 9, there was a notable difference in the scratching response elicited by both drugs examined (Fig. 7D). Indeed, within the first 30 min post-injection, morphine was found to produce a strong scratch reflex in rats that weakened over time.

### 3.5. Cardiovascular and respiratory effects induced by intrathecal PK23

Blood pressure and respiratory function in the PK23-treated group (10 nmol/rat, i.t.) was compared with saline-treated rats. As presented in Table 3, no changes in ventilation or heart rate were reported after i.t. administration of PK23. A visible, but insignificant decrease in arterial blood pressure (MAP) was noted immediately after injection that lasted for 30 s. At 1 min, the depressor response translated into an insignificant increase in MAP lasting about 5 min. MAP values returned to baseline within 10 min.

### 3.6. Stability of PK23 in rat plasma in vitro and blood–brain barrier permeability after i.v. administration

Plasma stability of PK23 was evaluated. The compound was not fully metabolized within the total experiment time (24 h). The peak representing PK23 was observed on BPC recorded in negative ion mode throughout the experiment (Supporting Information Fig. S1). Starting from 1 h incubation the occurrence of two peaks (A and B, in Fig. S1) in BPC was observed. Compounds A and B are the metabolic products of PK23 produced by plasma protease activity. The tentative chemical structures of A and B were proposed in Supporting Information Fig. S2 (Supplementary file). Compound A is a product of leucine and isoleucine cleavage at the C-end of PK23. Compound B was proposed as PK23 after the loss of phenylalanine present at the N-end of the investigated peptide.

Apart from plasma stability studies, also brain penetration of PK23 was assessed in our studies. Indeed, after a single intravenous administration at a dose of 5 mg/kg, the test chimera was found to penetrate the BBB, which was determined by HPLC experiments using brain homogenates (Supporting Information Fig. S3B).

### 4. Discussion

This paper describes the biological activity of PK23, a novel compound combining an opioid- and an NT-like pharmacophores. The presented chimeric ligand was found to exert a strong antinociceptive effect, but noticeably weaker in comparison to a previously reported PK20 and [Ile²]PK20 opioid–NT hybrids. Indeed, both PK20 and its analogue were shown to induce substantial pain-relief at doses approximately 500-times (0.02 nmol/rat; i.t.) and 100-times (0.1 nmol/rat; i.t.) lower than PK23 administered via the same route. However, intrathecal administration of PK20 at a dose higher than 10 nmol/rat led to sudden death of animals (data not published). Similar results were observed for our compound but administered...
intracerebroventricularly at 10 nmol/rat and higher. This in consequence did not allow us performing a dose–response analysis that would give a complete picture after its i.c.v. administration. Despite the relatively modest analgesic efficacy, data obtained with this new compound, however, provide essential information regarding structure modifications crucial for obtaining a potent analgesic with reduced side effects. In fact, substitution of 2,15-(Dmt) for the N-terminal Tyr in opioid peptides (as in PK20 chimera) has recently been shown as a promising tool for improving opioid receptor affinity and biological activity. However, it was shown that accordingly to the “message-address” concept 26,27 of opioid ligands, the lack of modification of the Tyr1 residue (as in PK23) that comprises the message component may still result in high affinity towards the opioid receptor, but with improved safety profile of the compound. Additionally, the attached modified pharmacophore of NT(8–13) may serve as an address domain which can modulate opioid peptide receptor selectivity, while maintaining specific interactions with the NT receptor. Furthermore, it was noticed that PK23 shows structural homology with the amphibian skin opioid peptide dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2), especially considering the first two N-terminally located amino acid residues that are also shared among all deltorphins. Moreover, this dipeptide fragment differentiates PK23 from its analogue, [Ile9]PK20. However, considering that Dmt incorporation within the N-terminal part of opioids plays an essential role in conferring high affinity to µ-opioid receptors, the role and functional diversity of various d-amino acids in position 2 of the sequence still remain controversial 28,29. Thus, the functionality of the specific d-amino acid residue while preserving the subsequent amino acids requires further examination. Nevertheless, the PK23-mediated pain-reducing activity was strongly evidenced after spinal administration (Figs. 1B and 2) suggesting that the main site of action of this opioid–NT hybrid peptide, is located at the spinal cord level. In fact, both the i.p. as well as i.v. delivery of PK23 was found to exert rather weak antinociceptive responses when compared to its central administration (Fig. 1C and D, respectively). However, although opioid-based ligands can produce analgesic effect through peripheral mechanisms, particularly in inflammatory state, one could assume their capacity to penetrate the blood–brain barrier. Indeed, brain uptake of PK23 following its single intravenous administration (5 mg/kg) to rats was shown in Fig. S3. Such a result seems to be intriguing since—according to the “Lipinski’s Rule of Five”—the optimal compound’s molecular mass desired for its sufficient BBB penetration should not exceed 400 Da; of note, the molecular weight of the PK23 chimera is equal 1273 Da. Nevertheless, further studies with multiple dosing may be performed in order to determine the potential of PK23 chimera to accumulate within the brain.

Apart from the analgesic effect, opioids and various opioid-based compounds are well-known for their ability to induce clinically significant side effects, in particular tolerance and dependence. The hybrid approach is aimed particularly at developing improved compounds with fewer or more discrete side effects. In 2016, we demonstrated that the responses obtained after administration of an opioid hybrid peptide or a combination of its pharmacophores are different 30. In particular, the hybrid which combines two distinct activities in a single molecular entity, caused no impairments of motor function. Similar results were later obtained for PK23.
Furthermore, the analgesic properties of this compound were preserved for a longer period of time as compared with morphine after subchronical administration (Fig. 4B). Importantly, morphine induced a severe loss of analgesic activity as soon as 3 days after initiating treatment. This may result from the different pharmacokinetic profiles of these two drugs. However, the mean elimination half-life of morphine ranges from 1.5 to 3.4 h\(^30\), while the half-life of PK23 reaches similar values (\(t_{1/2}\) at 3.13 h). However, being an analogue of PK20 (\(t_{1/2}\) at 31.45 h), PK23 was anticipated to show similar extended half-life values\(^13\). We also cannot exclude the hypothesis that the biochemical pathways responsible for termination of the compound actions and desensitization of functional \(\mu\)-opioid receptors differ.

The development of opioid receptor ligands associated with reduced tolerance is of major importance\(^31\). New ligands could be considered as substitutes for classical opioids or could be used in opioid rotation protocols to obtain a balance between pain control and the intensity of adverse effects.

There is evidence for the role of dopamine D2 receptors in the development of morphine tolerance as well as on some motor behaviors\(^32,33\). The possible activation of this dopamine receptor by PK23 was therefore examined in \([^{35}S]GTP\gamma S\) binding assay in transfected cells\(^31\). Dopamine produced a robust response (\(E_{\text{max}} = 140.92\%\)), while PK23 stimulated G protein activation with much lower efficacy (\(E_{\text{max}} = 117.13\%\)) (Kleckowska and Hermans, unpublished data). Even more convincing, while the response to dopamine was considerably reduced in the presence of domperidone, this dopamine receptor antagonist was without influence on the response to PK23. Although we did not further address the mechanism of lower side effect liability of PK23, some hypotheses explaining this phenomenon exist. Firstly, the effect observed may result from the activity of the NT-like pharmacophore, attachment of which could have resulted in the reduction of potency and selectivity of the compound to the \(\mu\)-opioid receptors. Such a phenomenon reflecting changes in the aforementioned features of a hybrid compound in comparison to a

### Table 3  Cardiovascular and respiratory effects of i.t. injected PK23.

| Factor     | PK23         | NaCl         |
|------------|--------------|--------------|
|            | Baseline     | 0 min        | MAX 10 min | Baseline | 0 min | MAX 10 min |
| \(V_E\) (mL/min) | 121 ± 12 | 118 ± 10 | 122 ± 13 | 113 ± 14 | 120 ± 8 | 119 ± 9 | 124 ± 5 | 120 ± 7 |
| HR (beat/min)    | 436 ± 24 | 439 ± 24 | 435 ± 31 | 418 ± 32 | 404 ± 33 | 403 ± 32 | 415 ± 33 | 411 ± 36 |
| MAP (mm Hg)      | 83 ± 4 | 76 ± 5 | 97 ± 8 | 87 ± 7 | 83 ± 5 | 83 ± 6 | 87 ± 6 | 84 ± 7 |

\(V_E\), minute ventilation; HR, heart rate; MAP, mean arterial blood pressure; Baseline, before injection, 0 min, early phase after injection, MAX, maximum value selected between 1 and 5 min after injection; \(n = 5\) for PK23 and \(n = 4\) for NaCl treated rats.
mixture of its pharmacophores, was already reported by Kleczkowska et al. Secondly, this effect may be due to some putative activity of PK23 at δ-opioid receptors. The involvement of this type of receptors in the development of opioid tolerance was confirmed in transgenic δ-opioid receptor knock-out mice. Hence, δ-opioid antagonists were found effective in preventing morphine tolerance. It is possible that with a putative mixed μ/δ activity, PK23 could modulate opioid receptor-mediated tolerance and dependence.

PK23-mediated antinociception and sustained pain-relieving effect after repeated administration could also be the consequence of its functional interaction with other nociceptive systems. Indeed, animals treated with doses higher than 10 nmol (i.c.v.) of PK23 exhibited behaviors such as barrel rotation, which are related neither to opioid nor NT receptors. Also, death occurred in some cases. Blockage of the β-adrenergic receptor was found to exert antinociceptive effects and thus could represent a potential target for PK23.

Apart from the hallmark features of opioids, like tolerance and dependence liability, NT is also known to elicit side effects like anorexia nervosa or hypotension. In our study, we did not observe reduced food intake or changes in the body temperature (data not shown) following subchronic i.t. administration of PK23. Additionally, PK23 affected neither the respiratory system nor induce hypotension. However, considering that the biological activity of PK23 resulted rather from the synergistic interactions between both of its pharmacophores, and given a strong involvement of the NTS1 receptor agonist activity, we expected this peptide to alter blood pressure. However, a single i.t. injection of PK23 in anaesthetized animals did not significantly change either blood pressure, heart rate or ventilation. What is more important, by careful dose titration and the right selection of the delivery route, we managed to avoid a prolonged hypotensive response described previously after i.t and i.v. administration of neurotensin (NT).

Several animals have reported that morphine elicits scratching and grooming behaviours in rodents, together with a series of other spontaneous signs accompanying nociceptive responses. In contrast, NT suppresses both grooming and scratching behaviour induced by several endogenous peptides, including β-endorphins and bombesin. Such observations are highly consistent with our data (Fig. 7). In fact, PK23 chimera was found to reduce or delay grooming and scratching behaviours, which could be explained by the presence of an NT-like structural component. Whilst morphine significantly increased the scratching reflex in rats, especially on day 9 (Fig. 7C), the effect induced by the tested peptide was almost similar to that observed for control. This however, was true only for the first 20 min post-administration as a similar response to PK23 and morphine occurred at later time points (between 20 and 30 min). Furthermore, attenuation of grooming behaviour reported for i.t. administered PK23 chimera (Fig. 7B and D) was also observed in our current study (in a substance P-induced grooming model; data not shown). These results clearly show that the C-terminal NT-like fragment is strongly involved not only in the antinociceptive activity exhibited by the chimera, but also in other of its properties.

5. Conclusions

The herein presented that the opioid–NT bivalent compound PK23 seems a promising analgesic with a favourable profile in terms of side effects, like reduced scratch reflex, delayed development of tolerance and no obvious signs of motor impairment when compared with the gold standard, morphine. However, numerous additional studies need to be performed in order to determine the possible mechanism of action of this novel chimera. Furthermore, extended characterization of the analgesic and possible side effects exerted by PK23 need to be performed to get a complete picture of the compound’s activity.

Acknowledgments

Research equipment implemented with CPB infrastructure financed by the EU—the European Regional Development Fund within the Operational Program “Innovative economy” for 2007–2013. This research did not receive any specific grants from funding agencies from the public, commercial, or not-for-profit sectors.

Author contributions

Patrycja Kleczkowska and Karolina Frączek participated in research design; Karolina Frączek, Mattia Ferraiolo, Kaja Kasarrello, Anna Erdei, Kamila Kulik, Agnieszka Kowalczyk, Sebastian Granica conducted the experiments; Emmanuel Hermans, Magdalena Bujańska-Zadrożny, Sandor Benyhe, Katarzyna Kaczynska, Łukasz Nagraba, Artur Stolarczyk, Agnieszka Cudnoch-Jedrzejewska and Patrycja Kleczkowska contributed reagents or analytic tool; Karolina Frączek, Mattia Ferraiolo, Kaja Kasarrello, Anna Erdei, Sebastian Granica, Katarzyna Kaczynska and Patrycja Kleczkowska performed data analysis; Karolina Frączek, Emmanuel Hermans, Anna Erdei, Sebastian Granica, Sandor Benyhe, Katarzyna Kaczynska and Patrycja Kleczkowska wrote or contributed to the writing of the manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

Appendix A. Supporting information

Supporting data to this article can be found online at https://doi.org/10.1016/j.apsb.2020.04.014.

References

1. DeHaven-Hudkins DL, Burgos LC, Cassel JA, Daubert JD, DeHaven RN, Mansson E, et al. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Therapeut 1999;289:494–502.
2. Hamed N, Sloan P. Safety concerns with long-term opioid use. Expert Opin Drug Saf 2016;15:955–62.
3. Lewis AB, Ferry DA, Sadeghi M. Fetal cardiovascular and breathing movement responses to endogenous opiates. Biol Neonate 1986;58:278–87.
4. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manag 1990;5:362–7.
5. Webster LR, Camilleri M, Finn A. Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals. Subst Abuse Rehabil 2016;7:81–6.
6. Whitman CB, Reid MW, Arnold C, Patel H, Ursos L, Sa’adon R, et al. Balancing opioid-induced gastrointestinal side effects with pain...
management: insights from the online community. *J Opioid Manage* 2015;11:383–91.
7. Yuill MB, Zee ML, Marcus D, Morgan DI. Tolerance to the antinociceptive and hypoalgesic effects of morphine is mediated by multiple isoforms of c-Jun N-terminal kinase. *Neuroreport* 2016;27:392–6.
8. Kleczykowska P, Hermans E, Kosson P, Kowalczyk A, Lesniak A, Pawlik K, et al. Antinociceptive effect induced by a combination of opioid and neurotensin moieties vs. their hybrid peptide [Ile⁶]PK20 in an acute pain treatment in rodents. *Brain Res* 2016;1648:172–80.
9. Kowalczyk A, Kleczykowska P, Rękawek M, Kulik K, Lesniak A, Erdei A, et al. Biological evaluation and molecular docking studies of AA3052, a compound containing a µ-selective opioid peptide agonist DALDA and α-Phe-α-Phe-Leu-Leu-γNH₂, a substance P analogue. *Eur J Pharmacol* 2016;93:11–20.
10. Dietz N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effects profile. *Br J Anaesth* 2009;103:38–49.
11. Morphy R, Rankovic Z. Designed multiple ligands: an emerging drug strategy to improve side-effects profile. *Br J Anaesth* 2009;103:38–49.
12. Clineschmidt BV, Martin GE, Veber DF. Antinocisponsive effects of Martin GE, Veber DF. Antinocisponsive effects of morphine induced by peripherally administered bromoephedrine. *J Med Chem* 1984;27:587–654.
13. Hermans E, Geurts M, Maloteaux JM. Agonist and antagonist modulation of [35S]GTPγS binding in transfected CHO cells expressing the neurotensin receptor. *Br J Pharmacol* 1997;121:1817–23.
14. Hermans E, Maloteaux JM, Octave JM. Phospholipase C activation by neurotensin and neumedin C in Chinese hamster ovary cells expressing the rat neurotensin receptor. *Mol Brain Res* 1992;15:332–8.
15. van Wimersma Greidanus TB, Maigret C, Ten Haaf JA, Spruijt BM, Colburn DL. The influence of neurotensin, naloxone, and haloperidol on elements of excessive grooming behavior induced by ACTH. *Behav Brain Biol* 1986;46:137–44.
16. van Wimersma Greidanus TB, van de Brug F, de Bruijcker LM, Pabst PH, Ruesink RW, Hulshof RL, et al. Comparison of bombesin-, ACTH-, and beta-endorphin-induced grooming. Antagonism by haloperidol, naloxone, and neuromedin. *Ann NY Acad Sci* 1988;525:219–27.
17. Clineschmidt BV, Martin GE, Veber DF. Antinocisresponsive effects of morphine induced by peripherally administered bromoephedrine. *J Med Chem* 1984;27:587–654.
18. Binder EB, Kinkade B, Owens MJ, Nemeroff CB. Neurotensin and naloxone, and haloperidol on elements of excessive grooming behavior induced by ACTH. *Behav Brain Biol* 1986;46:137–44.
19. van Wimersma Greidanus TB, Maigret C, Ten Haaf JA, Spruijt BM, Colburn DL. The influence of neurotensin, naloxone, and haloperidol on elements of excessive grooming behavior induced by ACTH. *Behav Brain Biol* 1986;46:137–44.